Abstract
Malignant pleural mesothelioma (MPM) is a virulent disease that is essentially incurable. Although surgery cannot currently be considered standard of care, there is general agreement that a certain subset of patients appear to benefit from surgery-based multimodal treatments beyond what would be expected with the current standard of care, pemetrexed-based chemotherapy alone. Exactly who those patients are remains to be defined. One intuitively appealing aspect of surgery-based therapies is that they allow for the employment of an intraoperative adjuvant therapy. There are multiple intraoperative adjuvant therapies, each with their own advantages and disadvantages. This chapter is a review of these treatments.
Keywords: Intraoperative therapy, intrapleural chemotherapy, outcomes, photodynamic therapy.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Aging Science
Anti-Infective Agents
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents